Interval between Surgery and Radiation Therapy Is an Important Prognostic Factor in Treatment of Rectal Cancer.
- Author:
Jin Hee KIM
1
;
Sang Jun BYUN
;
Seung Gyu PARK
;
Young Kee OH
;
Seong Kyu BAEK
Author Information
1. Department of Radiation Oncology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. jhkim@dsmc.or.kr
- Publication Type:Original Article
- Keywords:
Rectal neoplasms;
Adjuvant radiotherapy;
Drug therapy;
Prognosis
- MeSH:
Female;
Follow-Up Studies;
Humans;
Male;
Multivariate Analysis;
Neoplasm Metastasis;
Prognosis;
Radiotherapy, Adjuvant;
Rectal Neoplasms;
Retrospective Studies;
Survival Rate
- From:Cancer Research and Treatment
2012;44(3):187-194
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The purpose of this study is to evaluate survival and prognostic factors for rectal cancer, including interval between surgery and radiation therapy after surgery, radiation therapy, and chemotherapy. MATERIALS AND METHODS: We conducted a retrospective study of 153 patients with rectal cancer who were treated with surgery, radiotherapy with/without chemotherapy at Keimyung University Dongsan Medical Center from January, 1988 to December, 2005. The study included 89 males and 64 females, with a median age of 56 years (range, 23 to 81 years). Tumor, node and metastasis (TNM) was I in 23 patients, II in 39, and III in 91. Radiation therapy was performed on pelvic fields using a median dose of 54 Gy five days per week, 1.8 Gy once per day. Ninety two patients were treated with radiotherapy, 43 with concurrent chemo-radiation therapy and 18 with sequential therapy after surgery. The median follow-up period was 52 months (range, 4 to 272 months). The interval between surgery and radiation was 1-25 weeks (median, 5 weeks). RESULTS: Two-year and five-year overall survival rate was 64.7% and 46.4%, respectively. Two-year and five-year disease-free-survival (DFS) rate was 58.6% and 43.1%, respectively. Median DFS was 39 months. Loco-regional failure was evident in 10.5% of patients, 8.4% had distant metastasis, and 9.2% had both. In multivariate analysis, TNM stage and interval between surgery and radiation therapy (< or =5 weeks vs. >5 weeks; 95% confidence interval, 1.276 to 2.877; hazard ratio, 1.916; p=0.002) were significant prognostic factors of DFS. CONCLUSION: Survival rates for rectal cancer after surgery, chemotherapy, and radiation therapy were similar to those reported in previous studies. Starting radiation therapy as soon as possible after surgery, especially within the first five weeks after surgery, is suggested.
